a public good project by the
Synthesis
Company
of California

© 2026

Wim H.J. Kruit | doi.page

0 works0 citations0 h-index

Wim H.J. Kruit

Erasmus MC Cancer Institute(NL)

Publications by Year

Research Areas

Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses, CAR-T cell therapy research, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers

Most-Cited Works

→ Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience(2006)906 cited
→ Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial(2008)642 cited
→ Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy(2013)473 cited
→ Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial(2005)314 cited
→ Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma(2012)281 cited
→ Side Effects of Interferon-α Therapy(2005)280 cited

→ Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma(2013)218 cited

→ Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)(2011)210 cited

→ MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial(2018)193 cited

→ Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial(2007)190 cited